Dr Reddy’s Laboratories has moved higher by 1% to Rs 2,315 after the company said it has launched Decitabine for injection, a therapeutic equivalent generic version of Dacogen in the US market on July 11, 2013.
The company has launched Decitabine for injection following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Decitabine for Injection, Dr Reddy’s Lab said in a press release.
The Dacogen brand has US sales of approximately $260 Million MAT for the most recent twelve months ending in July 2013 according to IMS Health. Dr Reddy’s Decitabine for injection 50 mg is available as a single dose vial, it added.
Meanwhile, the foreign institutional investors (FIIs) have increased their holdings in Dr Reddy’s Laboratories by over 3 percentage points to 32.69% during June 2013 quarter. FIIs held 29.66% stake at the end of March 2013 quarter.
The stock opened at Rs 2,301 and hit a record high of Rs 2,317 on NSE. A combined 158,729 shares have changed hands on the counter so far on NSE and BSE.
The company has launched Decitabine for injection following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Decitabine for Injection, Dr Reddy’s Lab said in a press release.
The Dacogen brand has US sales of approximately $260 Million MAT for the most recent twelve months ending in July 2013 according to IMS Health. Dr Reddy’s Decitabine for injection 50 mg is available as a single dose vial, it added.
Meanwhile, the foreign institutional investors (FIIs) have increased their holdings in Dr Reddy’s Laboratories by over 3 percentage points to 32.69% during June 2013 quarter. FIIs held 29.66% stake at the end of March 2013 quarter.
The stock opened at Rs 2,301 and hit a record high of Rs 2,317 on NSE. A combined 158,729 shares have changed hands on the counter so far on NSE and BSE.
